NUTX · Nutex Health Inc. · Stock research

Refresh of coverage first published 2026-07-02; last updated 2026-08-15.

NUTX — Nutex Health, Inc.

Current Thesis

The post-print re-rating held, then stopped extending. NUTX closed $185.84 on 2026-08-21 against $187.42 on 2026-08-14 — six sessions of sideways action, 5.9% below the 52-week high of $197.51, with RSI(14) at 64.0 and a three-month price change of +56.3%. Nothing external arrived in that window: no rating change since Lake Street's 2026-08-11 raise to $310 from $235, no new filing, and the only company headline was the 2026-08-18 opening of a West Little Rock emergency hospital in Arkansas. The narrative content is unchanged from the 2026-08-06 print — the cost of collecting No Surprises Act arbitration revenue was structurally reset (contract services expense $1.1M in Q2 FY2026 against $61.1M a year prior, a $52.3M reduction, plus the CMS federal IDR administrative fee cut from $115 to $15 per party per dispute effective 2026-06-11) — but the flow behind it has moderated. The narrative is maturing. The prior accelerating label was dated to the 2026-08-06 print and the 2026-08-11 target raise; the conditions that supported it — fresh coverage, expanding participation, new highs — have not repeated in the seven sessions since, while the structure itself is intact. What is genuinely unresolved is whether the Q2 cost line was a retroactive credit or a run-rate, and that does not resolve until the Q3 print in early November.

Bullish and bearish views on Nutex Health Inc.

The model's bull view on Nutex Health Inc. (NUTX), in brief: Cost relief is filed, not guided. Contract services expense of $1.1M in Q2 FY2026 versus $61.1M a year earlier, disclosed in the 2026-08-06 release. The CMS fee cut to $15 per party per dispute took effect 2026-06-11 by rule. Cash conversion. Six-month operating cash flow of… The bear view: Q2 EPS is not a run-rate. The HaloMD fee amendment moved certain fees to pay-on-collected terms retroactive to the original 2024-05-01 contract date, so the June quarter absorbed credits belonging to eight prior periods. A $1.1M contract services line does not repeat. The first… Both cases follow in full.

Bull Case

• Cost relief is filed, not guided. Contract services expense of $1.1M in Q2 FY2026 versus $61.1M a year earlier, disclosed in the 2026-08-06 release. The CMS fee cut to $15 per party per dispute took effect 2026-06-11 by rule.
• Cash conversion. Six-month operating cash flow of $109.7M to 2026-06-30, up from $78.2M. Cash and cash equivalents $205.2M plus $1.9M restricted at 2026-06-30, against long-term debt net of $31.1M.
• Capacity is still being added. The West Little Rock emergency hospital opened per the company release of 2026-08-18 — the third Arkansas facility, and characterised by Simply Wall St's 2026-08-20 piece as the 28th nationwide. Six-month visits 99,704, +6.2%, same-hospital +3.4%.
• Share count is shrinking, not growing. $50.7M of common stock repurchased in the six months to 2026-06-30, following roughly $30.4M of insider purchases reported in the quarter ended 2026-03-31. No equity issuance into the August strength has been disclosed.
• Arbitration mechanics reaffirmed on the 2026-08-06 call: 50–60% of claims routed through IDR, prevailing in over 85% of award determinations, collecting on average over 80% of award amounts.
• Published targets sit well above the tape. B. Riley Buy/$290 (2026-06-26); Lake Street Buy/$310 (2026-08-11). Aggregators show roughly five covering analysts, average target near $266.40, high $310, low $200, against the 2026-08-21 close of $185.84.

Bear Case

• Q2 EPS is not a run-rate. The HaloMD fee amendment moved certain fees to pay-on-collected terms retroactive to the original 2024-05-01 contract date, so the June quarter absorbed credits belonging to eight prior periods. A $1.1M contract services line does not repeat. The first clean read is the quarter ending 2026-09-30, reported in early November.
• Revenue keeps falling. $216.5M in Q1 FY2026, $210.752M in Q2 — a 13.6% YoY decline from $244.0M and a miss against the $215.031M consensus. Visit growth of +9.6% did not offset arbitration mix.
• The $55.0M cumulative true-up of 18,950 ineligible IDR claims (Jul-2024 to Dec-2025) already sits in reported history. Eligibility screens are applied retroactively, so the mechanism that produced one reset can produce another.
• Legal overhang unresolved. The SEC inquiry into disclosure of HaloMD's legal exposure and arbitration-revenue collectibility remains open, alongside a securities class action and a derivative suit stemming from the 2025-07-22 Blue Orca short report.
• Regulatory dependence cuts both ways. The same federal IDR process that delivered the fee cut sets claim eligibility; a rulemaking change reprices the revenue model directly.
• Coverage is thin enough to reverse. Five houses carry the name. One downgrade from either B. Riley or Lake Street moves the consensus target materially and removes the bid that followed the print.

Setup & Price Structure

Reference close 2026-08-21: $185.84, with the 52-week high at $197.51 on the adjusted daily series. The structure runs: the 2026-07-17 close of $162.98 after five straight down days marked the failure of the June breakout; the 2026-08-06 print gapped price out of that stall — Simply Wall St put the post-print advance at +29.2% — and the tape has since consolidated in a narrow band beneath the August high rather than reversing. RSI(14) at 64.0 is elevated without being stretched.

Crowding and positioning observables, stated as observables: sell-side coverage went from one house on 2026-06-26 to roughly five by 2026-08-11, an expansion of attention concentrated in seven weeks; the consensus target of ~$266.40 sits about 43% above the 2026-08-21 close, which is a wide gap for a name with an unresolved SEC inquiry; no earnings date falls inside the next 30 days; and the company has been buying stock rather than selling it, with $50.7M repurchased in the six months to 2026-06-30 and no disclosed issuance into strength. The float mechanics remain the dominant driver of single-session range — a single 8-K has repeatedly produced double-digit moves in both directions.

Catalyst Calendar (next 30 days)

• ~2026-09-09 (est.) — Nasdaq publication of short interest for the 2026-08-31 settlement date. First reading that spans the entire post-print advance.
• 2026-09-15 (est.) — Nasdaq publication cycle for the mid-September settlement, if the prior reading shows a material change in the short base.
• 2026-09-30 — Q3 FY2026 quarter-end. The first full period governed by both the amended HaloMD fee terms and the $15 CMS administrative fee. Falls just outside the 30-day window but sets the content of the November print.
• No scheduled earnings, guidance event, investor conference or index rebalance affecting the name has been identified inside the 30-day window. The next hard binary is the Q3 report, estimated ~2026-11-05.

What Would Change Our Mind

The structure that matters now is the shelf built after 2026-08-06, not the June breakout that already failed once. Losing it would say the print was re-rated on a number the market subsequently decided was non-recurring. A weekly close below $162 forfeits the entire post-print advance and returns price into the July stall zone where the last breakout attempt died at the 2026-07-17 close of $162.98; that is the gradeable break.

Three non-price conditions would change the read independently of the tape. First, the Q3 FY2026 print showing contract services expense returning toward the $61.1M pre-amendment level rather than settling at a materially lower normalized figure — this is the single number that decides whether the earnings inflection is structural. Second, any further disclosed reversal of previously recognized arbitration revenue, in a 10-Q or 8-K, which would convert the $55.0M true-up from a one-time cleanup into a recurring reset. Third, escalation of the SEC inquiry — a Wells notice, an enforcement action, or an Item 4.02 non-reliance filing.

Conditions that would move the label back to accelerating: a close above the $197.51 52-week high on expanding volume, a sixth covering analyst, or a short-interest reading for the 2026-08-31 settlement showing the base rebuilt against a ~7M share count.

Correlation Notes

• Correlation to large hospital operators (HCA, THC, UHS) is weak in practice: those names trade on admissions volume, payer mix and labour cost, while NUTX's earnings swing in Q2 FY2026 came from an arbitration-vendor fee amendment and a CMS administrative fee schedule.
• The genuine shared factor is federal No Surprises Act IDR policy, which it holds with air-ambulance and physician-staffing operators exposed to out-of-network arbitration. A CMS/DOL/HHS rulemaking headline moves that cohort together.
• HaloMD is private, so there is no listed proxy for the counterparty whose fee structure drove the Q2 result; the only read-through arrives through Nutex's own filings.
• With roughly 7M shares outstanding and short interest last reported near 13.84%, index and small-cap flow can dominate the daily print independently of fundamentals; day-to-day moves should not be read as information about the arbitration model.
• The stock's beta to its own single-headline risk is far higher than its beta to any sector index — the July drawdown and the August advance were both company-specific and neither tracked healthcare-sector moves.